Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

GROWTH FACTORS ( BLOOD AND TISSUE ) - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in US$ Million by the following growth factor types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 90 companies including many key and niche players such as Alseres Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance GeneMedix Plc, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1217
Price : $4500
Companies : 90
Pages : 560
Date : January 2011
Market Data Tables : 42

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  GROWTH FACTORS ( BLOOD AND TISSUE ) (Complete Report) Pages : 560   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......14 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2
Data Interpretation & Reporting Level.......2
  
   Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
  
   Blood Growth Factors.......4
Erythropoietins.......4
Colony Stimulating Factors.......4
Interferons.......4
Interleukins.......4
Tissue Growth Factors.......4
  
  2. INTRODUCTION........65 $595  
   Growth Factors: A Preface........6
Current and Future Analysis........6
Analysis By Region........6
US - The Single Largest Market........6
Growth Factors Market in Europe........6
Market for Growth Factors in Rest of World........6
1$100
   Table 1: World Market for Growth Factors (2007-2015): Geographic Regions Ranked by CAGR – US, Japan, Rest of World, and Europe (includes corresponding Graph/Chart)........7
Analysis by Growth Factor Type........7
1$350
   Growth Factors: Their Role and Related Applications........8
Growth Factors: Adding a New Dimension........8
Growth Factors: Classification Based on Activity........8
Recent Trends & Developments........8
1$100
   Recombinant Human Erythropoietin: Gradually Gaining Dominance........9
Leading EPO Drugs Worldwide........9
Market Comparison of Erythropoietin-Based Drugs in America and European Union........9
1$100
   Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007........10
Patent Expiries of Select Biopharmaceuticals in Europe and United States: 2010 and
  Beyond........10
1$100
  3. MARKET DYNAMICS........113 $295  
   Major Companies Impacted by Patent Expiries........11
Patent Expiries Fuel Competition and Sales........11
Side Effects – Still a Concern........11
CDER- A Regulatory Review Authority for Growth Factors........11
1$100
   Innovative Delivery System Shows Potential for Accelerating Use of Growth
  Factors........12
Cytokines- Vital Growth Propellers for the Future of New Drugs........12
Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application........12
Age-Related Diseases – Their Influence on Effective Therapies........12
1$100
   Mimetic Growth Factors – Exhibiting Promising Potential........13
India – At the Center Stage ........13
1$100
  4. INDUSTRY ISSUES........14   
   Development of Cost Effective Methods – Need of the Hour........14
Influence of Neurotrophic Factors on Brain Cell Development........14
Combination of Interferons and Ribavirin Develops More Anemia Cases........14
1$100
  5. GROWTH FACTORS – AN OVERVIEW........1513 $1950  
   Blood Growth Factors........15
Erythropoietins........15
1$100
   Types of Erythropoietins........16
Epoetin........16
Darbepoetin........16
Aranesp®........16
Aranesp Vs. Other EPOs........16
Recombinant Human EPO (rHuEPO)........16
1$100
   Table 2: World Market for Erythropoietins (2007-2015): Geographic Regions Ranked by CAGR –Rest of World, Japan, US and Europe (includes corresponding Graph/Chart)........17
Colony Stimulating Factors........17
Granulocyte-Colony Stimulating Factor........17
1$350
   Granulocyte Macrophage-Colony Stimulating Factor........18
Other Colony Stimulating Factors........18
Macrophage Colony Stimulating Factor (M-CSF)........18
Key Functions of M-CSF........18
Side-Effects of Colony-Stimulating Factors........18
1$100
   Table 3: World Market for Colony Stimulating Factors (2007-2015): Geographic Regions Ranked by CAGR - Europe, US, Japan and Rest of World (includes corresponding Graph/Chart)........19
Interferons........19
Types of Interferons........19
1$350
   Interferon-gamma........20
1a and 1b: Two Key Biochemical Forms of Interferon-ß........20
PEG-Intron........20
Types of Interferons........20
1$100
   Table 4: World Market for Interferons as Blood Growth Factors (2007-2015): Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)........21
Interleukins........21
Types of Interleukins........21
1$350
   Table 5: World Market for Interleukins as Blood Growth Factors (2007-2015): Geographic Regions Ranked by CAGR - Europe, Rest of World, Japan and US (includes corresponding Graph/Chart)........221$350
   Tissue Growth Factors........23
Wound Healing Growth Factors........23
Neurotrophic Growth Factors........23
Nerve Growth Factor........23
Vascular Endothelial Growth Factor (VEGF)........23
1$100
   Fibroblast Growth Factor (FGF)........24
Insulin-Like Growth Factor-I (IGF-I)........24
Insulin-Like Growth Factor-II (IGF-II)........24
Tissue Growth Factors: Classification Based on Key Source and Principal Activity........24
Platelet – Derived Growth Factors in Wound Healing........24
1$100
   Thrombopoietin (TPO)........25
Table 6: World Market for Tissue Growth Factors (2007-2015): Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)........25
Growth Factors: Their Mode of Action in Tissue Repair........25
1$350
   Angiogenesis: Their Role in Wound Healing........26
Angiogenesis As an Alternative for Cardiac Stents........26
Applications of Growth Factors........26
1$100
   Growth Factors: Suppliers and Applications........27
Growth Factors: Site/Course of Action and Applications........27
1$100
  6. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST PERSPECTIVE........287 $595  
   Maxygen Updates on Factor VII Program........28
Evaluation of Extended Dosing Schedule of PROCRIT®........28
PROCRIT® - A Better Option........28
Nerve Growth Factor Shows Promising Potential Against Diabetes........28
1$100
   Cytokines and GM-CSF Found to be Closely Interlinked........29
GM-CSF Enhances Rate of Survival in Neonates........29
1$100
   rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients........30
rG-CSF- Their Influence on Preterm Infants with Sepsis........30
Serum Macrophage Colony Stimulating Growth Factors Associated with Thrombocyte and
  Monocyte........30
Src Pathway Inactivation in Kit Impairs Blood Cell Growth and Proliferation........30
1$100
   Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth of Blood
  Vessels........31
Effect of Brain Derived Neurotrophic Factor on Retinal Cells........31
1$100
   Orcel™ Exhibits High Growth Factor for Wound Healing and Cardiovascular
  Applications........32
Drug Combination of Macrophage Colony Stimulating Factor Shows Successful Tolerance
  Levels........32
Neotrofin™ Triggers Neurotrophic Factors........32
1$100
   G-CSF Shows Capability for Promoting Neutrophil Production........33
Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing
  Process........33
1$100
   Hepatocyte Growth Factors – Exhibiting Dual Role........34
Cortex Pharmaceuticals Ampakines® Promotes Expression of Neurotrophin........34
Granulocyte Colony Stimulating Factor Finds Application in Treating Neonates........34
Cerebrolysin Promotes Cognition........34
1$100
  7. BREAKTHROUGHS – A RECENT PAST REVIEW........355 $395  
   Novel Set of Human Cytokines Unveiled........35
IGFBP-3 and its Potential to Ward Off Gastric Cancer........35
Bone Morphogenic Proteins Show Potential for Musculoskeletal Regeneration........35
Growth Factors – Their Role in Preventing Heart Stroke........35
Growth Factor Proteins Show Promising Results for Treating Cancer........35
1$100
   Neurotrophic Growth Factor - Primarily Responsible for Loss of Vision........36
Redox-Active Grape Seed Exhibits Favorable Properties for Dermal Wound Healing........36
Role of Brain-Derived Neurotrophic Factor on Memory........36
Nerve Growth Factor Found to Enhance Barium Current and Insulin Secretion........36
1$100
   Lipid Peroxidation May be Associated with Wound Healing........37
Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels........37
Connective Tissue Growth Factor Found to Promote Lung Fibroblast........37
1$100
   Influence of Insulin-Like Growth Factor on Growth........38
Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and Repair........38
Environment and Insulin-Like Growth Factors Stimulate Risk of Cancer........38
Cocktail of Neurotrophic Factors Promotes Regeneration of Torn Nerves........38
1$100
   Growth Factors Administration to Stimulate Tissue Repair........39
Cytokine – Their Role in Combating Hepatitis C Virus........39
Axokine® Yields Favorable Results Against Obesity........39
Cell Genesys Unveils GDNF Gene Therapy Targeted Against Parkinson’s Disease........39
1$100
  8. PRODUCT LAUNCHES........404 $295  
   Sandoz Unveils Zarzio........40
Wockhardt Launches Three Biotechnology Products........40
Extavia® Receives Approval from European Commission........40
1$100
   Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric Patients........41
Hospira Receives EC Approval on Retacrit........41
Tercica Receives FDA Approval For Increlex........41
Ventria Bioscience Introduces Lacromin........41
Dragon Pharmaceuticals Bags Market Approval from Chinese SDA........41
1$100
   DPI Receives Approvals for Erythropoietin in Three New Markets........42
Wockhardt Introduces Wepox Recombinant Erythropoietin Drug........42
Shanta Biotechnics Unveils Shanferon........42
SkinMedica Unveils TNS Recovery Complex™ Gel........42
CellGenix Unveils Cytokines for Cell Applications........42
1$100
   Cel-Sci Corporation Develops Multikine 43 Wockhardt Limited Unveils EPOX™........431$100
  9. RECENT INDUSTRY ACTIVITY........444 $295  
   Soluble Systems Collaborates with LifeNet Health’s Subsidiary to Introduce
  TheraSkin™........44
GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership........44
Kaken Pharmaceutical Enters into Licensing Agreement with Olympus Corporation........44
1$100
   Biovitrum and Amgen Sign Agreement........45
Merck Establishes Production Unit........45
Eli Lilly and Company Acquires ImClone Systems........45
1$100
   GeneMedix Changes Name to Reliance GeneMedix........46
FDA Approves Label Expansion for VIDAZA........46
Pfizer Inks Exclusive Global Licensing Agreement with Scil Technology........46
1$100
   ZGEN Initiates Ph II Trial of Interleukin 21........47
FzioMed Bags Health Canada Approval on Oxiplex®........47
NsGene A/S Implants Encapsulated Cell in Patients........47
1$100
  10. INDUSTRY ACTIVITY IN RECENT PAST – A PERSPECTIVE BUILDER........4816 $950  
   Reliance Life Sciences Takes Over Genemedix........48
Fraunhofer Institute Introduces First Interferon Beta 1a to Treat Multiple
  Sclerosis........48
Shanghai Wanxing Inks Export Deal for Recombinant Human Interferon........48
1$100
   Hemispherx Enters into Distribution Agreement with Armada........49
Bayer Establishes US Pharmaceuticals Subsidiary........49
Merck Inks Agreement with Bristol-Myers Squibb and ImClone........49
CoGenesys Signs Global Licensing Agreement with Vegenics........49
1$100
   InterMune Inks New Supply Deal with Boehringer Ingelheim........50
Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals........50
Cambrex Divests Bioproducts and Biopharma Subsidiaries........50
1$100
   Dragon Divests EPO Business........51
Caregene and Genzyme Forms Partnership to Develop Cere-120........51
NsGene to Undertake Phase Ib Clinical Trial of NsG0202........51
Roche Receives European approval for NeoRecormon........51
1$100
   Bolder Receives Two U.S. Patents for Hematopoietic Factors........52
RLS to Initiate Clinical Trials of Erythropoietin........52
InterMune Drops Phase III trial of Interferon........52
Chugai to Conduct Additional Trial on Epogin®........52
Merck KGaA Acquires Serono Labs........52
1$100
   CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences........53
Hospira Signs Agreements with STADA and BIOCEUTICALS for Erythropoietin........53
Biocon Bags GEAC Approval to Conduct Clinical Trial of Granulocyte Colony Stimulating
  Factor........53
SII to Conduct Clinical Trials of Rdna Products........53
1$100
   Claris to Construct Production Facility for EOP........54
Mayne and Pliva to End Collaboration on Erythropoietin Development........54
GeneMedix Collaborates with CJ Corp.........54
FzioMed and USC Enter into Licensing Agreement for Oligopeptides........54
1$100
   AnGes MG Enters Into An Agreement with Vical........55
Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA........55
Dragon Pharmaceuticals Acquires Oriental Wave........55
Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series........55
Amrad and Ludwig Institute Jointly Focus on the Development of VEGF-B........55
1$100
   GeneMedix Restructures Business........56
pSivida Limited Collaborates with Ian Wark Research Institute........56
Amgen Acquires Tularik........56
BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™........56
Chugai and Roche Expand Drug Research Synergies........56
1$100
   Dragon Pharmaceuticals to Construct New Production Facility........57
FibroGen Signs Contract with Yamanouchi for Licensing EPO Small Molecule........57
Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine........57
Maxygen and Rentschler Enter into a Contract for G-CSF........57
Maxygen Signs Agreement with Biovitrum for Manufacturing Beta Interferon........57
1$100
   Dragon Pharmaceuticals Signs Agreement with Zhongkai........58
Dragon Pharmaceuticals Enters into Definitive Agreement with Oriental Wave........58
Zymogenetics Bags US FDA Clearance........58
Ceregene Bags Patent........58
AME Enters into Third Collaboration with Eli Lilly and Company........58
1$100
   ViaCell Enters into Licensing Agreement and Collaboration with Amgen........59
Ceregene Enters into Licensing Agreement with Genentech........59
BIOPHARM GmbH Enters into Licensing Contract with DePuy........59
Maxygen Enters into a Deal with Roche Holding........59
1$100
   GeneMedix Signs Agreement with SkyePharma........60
Neurotech Enters into Licensing Agreement with Amgen........60
Ceregene Enters into a Licensing Agreement with Washington University........60
NeoTherapeutics Receives US Patent for Stimulating Neuritogenesis........60
BioSET Bags Global Exclusive License for Novel Growth Factor Technology........60
ViaCell Acquires Cerebrotec........60
1$100
   Fibrogen Collaborates with Sankyo........61
Prescient NeuroPharma Collaborates with SRIB........61
Dragon Pharmaceuticals Signs Agreement with Renapharm AB and Transworld........61
Baxter Bags Exclusive Worldwide Rights for Epoetin Omega........61
Ortec International Bags FDA PMA for OrCel........61
1$100
   GeneMedix Bags Chinese SDA Approval........62
NsGene Collaborates with ARIAD Pharmaceuticals........62
Regeneron Enters into Agreement with Emisphere Technologies........62
NsGene A/S Signs Agreement with Biogen Inc........62
1$100
   NTB Enters into BioInformatics Outsourcing Agreement with HSC........631$100
  11. FOCUS ON SELECT GLOBAL PLAYERS........648 $595  
   Alseres Pharmaceuticals, Inc. (USA)........64
Amgen, Inc. (USA)........64
Bayer HealthCare Pharmaceuticals Inc. (USA)........64
1$100
   BioMimetic Therapeutics, Inc. (USA)........65
Biopharm GmbH (Germany)........65
Bolder Biotechnology, Inc. (USA)........65
Ceregene, Inc. (USA)........65
1$100
   FibroGen, Inc. (USA)........66
FzioMed, Inc. (USA)........66
Novo Nordisk A/S (Denmark)........66
Reliance GeneMedix Plc. (UK)........66
1$100
   Insmed, Inc. (USA)........67
Johnson & Johnson (USA)........67
1$100
   Janssen-Ortho, Inc. (Canada)........68
Lonza Group (Switzerland)........68
Maxygen, Inc. (USA)........68
1$100
   Merck Serono International S.A. (Switzerland)........69
NsGene A/S (Denmark)........69
PeproTech, Inc. (USA)........69
Rentschler Biotechnologie GmbH (Germany)........69
1$100
   F. Hoffmann-La Roche Ltd (Switzerland)........70
Chugai Pharmaceutical Co. Ltd. (Japan)........70
Genentech, Inc. (USA)........70
1$100
   Shantha Biotechnics (India)........71
Scil Proteins GmbH (Germany)........71
Wockhardt Ltd. (India)........71
1$100
  12. GLOBAL MARKET PERSPECTIVE........72   
   Table 7: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........721$350
   Table 8: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........731$350
   Table 9: World 11-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........741$350
   Table 10: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........751$350
   Table 11: World Historic Review for Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........761$350
   Table 12: World 11-Year Perspective for Blood Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........771$350
   Table 13: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type – Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........781$350
   Table 14: World Historic Review for Blood Growth Factors by Type – Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........791$350
   Table 15: World 11-Year Perspective for Blood Growth Factors by Type – Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........801$350
   Table 16: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........811$350
   Table 17: World Historic Review for Erythropoietins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........821$350
   Table 18: World 11-Year Perspective for Erythropoietins by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........831$350
   Table 19: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........841$350
   Table 20: World Historic Review for Colony Stimulating Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........851$350
   Table 21: World 11-Year Perspective for Colony Stimulating Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........861$350
   Table 22: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........871$350
   Table 23: World Historic Review for Interferons as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........881$350
   Table 24: World 11-Year Perspective for Interferons as Blood Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........891$350
   Table 25: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........901$350
   Table 26: World Historic Review for Interleukins as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........911$350
   Table 27: World 11-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........921$350
   Table 28: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........931$350
   Table 29: World Historic Review for Tissue Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........941$350
   Table 30: World 11-Year Perspective for Tissue Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........951$350
  13. THE UNITED STATES........964 $950  
   A. Market Analysis........96
Current and Future Analysis........96
Leading EPO Drugs in the US........96
1$100
   B. Market Analytics........97
Table 31: US Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........97
1$350
   Table 32: US Historic Review for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........981$350
   Table 33: US 11-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........991$350
  14. JAPAN........1004 $950  
   A. Market Analysis........100
Current and Future Analysis........100
Erythropoietin Market........100
Leading EPO Drugs in Japan........100
Market Scenario for Biotech Products........100
Biotech Market Backed by Public Assistance........100
1$100
   B. Market Analytics........101
Table 34: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........101
1$350
   Table 35: Japanese Historic Review for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1021$350
   Table 36: Japanese 11-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........1031$350
  15. EUROPE........1044 $950  
   A. Market Analysis........104
Current and Future Analysis........104
Erythropoietin Market Scenario in the Recent Past........104
Leading EPO Drugs in Europe........104
1$100
   B. Market Analytics........105
Table 37: European Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........105
1$350
   Table 38: European Historic Review for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1061$350
   Table 39: European 11-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........1071$350
  16. REST OF WORLD........1085 $950  
   A. Market Analysis........108
Current and Future Analysis........108
An Overview of Indian Market........108
Erythropoietin........108
1$100
   G-CSF Market........109
Interferon........109
1$100
   B. Market Analytics........110
Table 40: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........110
1$350
   Table 41: Rest of World Historic Review for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........1111$350
   Table 42: Rest of World 11-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........1121$350
COMPETITION 435$995
  
Total Companies Profiled: 90 (including Divisions/Subsidiaries - 102)

Region/Country                 Players


The United States                 54    
Canada                             3
Japan                              5
Europe                            22 
     Germany                      12 
     The United Kingdom            2
     Rest of Europe                8
Asia-Pacific (Excluding Japan)    14 
Middle East                        4
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign